Clinical Trials Day 2026

Clinical Trials Day 2026

Each year on May 20th, the global research community marks International Clinical Trials Day [1]. The date commemorates the anniversary of James Lind’s 1747 scurvy experiment aboard HMS Salisbury, an event widely regarded as the first controlled clinical trial [2]. In 2026, celebrations worldwide focus not only on historical milestones but also on the transformative role of artificial intelligence (AI) in reshaping how trials are designed, conducted, and analysed. From virtual symposia on adaptive designs to workshops on AI-powered patient recruitment, this year’s activities reflect a field that has become vastly more sophisticated while retaining Lind’s core principle: structured comparison to find what truly works.

The First Trial: A Model of Simplicity and Insight

Lind’s original experiment was remarkably elegant. He recruited 12 sailors with similar scurvy symptoms, divided them into six pairs, and provided each pair with a different dietary supplement, cider, vinegar, seawater, a nutmeg-and-garlic elixir, oranges and lemons, or continued ship’s rations [3]. The pair receiving citrus fruits recovered rapidly, providing clear evidence that vitamin C prevented and treated scurvy.

Crucially, Lind was cautious in interpreting his results, questioning whether the citrus effect might be due to other factors. This humility, acknowledging the limits of one’s own data, remains a hallmark of good science. However, Lind’s trial lacked key features we now take for granted: randomisation, blinding, placebo control, and formal statistical analysis. It was a controlled trial in design but not yet a randomised controlled trial (RCT) [4].

From Lind to the RCT: A Journey of Rigour

The evolution from Lind’s 18th‑century comparison to today’s RCTs required centuries of methodological and ethical progress. In 1834, Pierre Louis used numerical methods to debunk bloodletting, showing that earlier intervention did not improve outcomes [5]. Florence Nightingale’s graphical presentations of mortality data during the Crimean War demonstrated the power of statistics in public health [6]. What might more correctly be considered the first modern RCT, the 1948 British Medical Research Council streptomycin trial for tuberculosis, introduced random allocation and concurrent control groups, establishing the RCT as the gold standard [7].

Ethical frameworks followed more slowly. The Nuremberg Code (1947) mandated informed consent after Nazi atrocities, while the Declaration of Helsinki (1964) and the Belmont Report (1979) enshrined respect for persons, beneficence, and justice [8][9 Tim]. These principles now underpin every legitimate clinical trial. The Tuskegee syphilis study, where treatment was withheld from Black men without their knowledge, remains a chilling reminder of why ethics cannot be an afterthought [10 Tim].

Global Activities in 2026: AI at the Forefront

This Clinical Trials Day, professional bodies, academic centres, and patient groups are hosting events that highlight AI’s growing footprint. Sessions include:

• AI‑assisted protocol design: Using machine learning to predict trial success and identify optimal endpoints [11].
• Decentralised and digital trials: Leveraging wearables, telemedicine, and remote consent to increase access and diversity [12].
• Real‑world data (RWD) and synthetic control arms: Using electronic health records to supplement or replace placebo groups, reducing patient exposure to ineffective treatments [13].
• Bias detection algorithms: Tools that audit trial populations for underrepresentation of women, ethnic minorities, and older adults [14].

These activities reflect a broader consensus: AI is not merely an efficiency tool but a means to correct historical shortcomings, such as poor diversity and slow recruitment, while (we hope) maintaining scientific rigour.

The Contribution of AI: Promise and Caution

Modern AI can scan millions of patient records to identify eligible participants in days rather than months. It can optimise adaptive trial designs, allowing pre‑planned modifications based on interim results without compromising statistical validity [15]. Generative AI assists in writing patient‑friendly informed consent forms and in monitoring adverse events through natural language processing of clinical notes.

Yet caution is warranted. AI models trained on biased data may perpetuate or amplify existing disparities [16]. Black‑box algorithms can obscure the reasoning behind treatment allocation or safety signals, challenging transparency. Therefore, regulatory bodies such as the FDA and EMA are developing guidance on “good machine learning practice” to ensure that AI complements, not replaces, human oversight [17].

Reflecting on Importance: Why Trials Remain Indispensable

Despite AI’s advances, the fundamental question asked by Lind—which of these interventions works better?, remains unchanged. RCTs are still the most reliable way to establish causality, and they depend on the voluntary participation of human beings. Without participants willing to trust the process, no algorithm can generate evidence.

This year’s commemorations also honour trial volunteers and the research teams who run complex global studies. As one organiser noted, “AI will never replace the courage of the first participant in a Phase I oncology trial” [1].

Conclusion: From Scurvy to Sequences

International Clinical Trials Day 2026 bridges a 279‑year arc: from a ship’s surgeon with a dozen sailors to global networks powered by machine learning. What remains constant is the commitment to evidence, ethics, and improvement. As Louis Pasteur observed, “Chance favours the prepared mind,” and today, AI helps prepare that mind faster, but it cannot replace the human judgment that gives trials their meaning.

References

1. Hardman T. From ancient history to AI-powered research. LinkedIn. 2025 May 20.
2. Applied Clinical Trials. Clinical Trials Day: Celebrating 275 years since the first controlled trial. 2024 May.
3. Lind J. A treatise of the scurvy. Edinburgh: Sands, Murray and Cochran; 1753.
4. Dunn PM. James Lind (1716-94) of Edinburgh and the treatment of scurvy. Arch Dis Child Fetal Neonatal Ed. 1997 Jan;76(1):F64-5.
5. Morabia A. Pierre-Charles-Alexandre Louis and the evaluation of bloodletting. J R Soc Med. 2006;99(3):158-60.
6. McDonald L. Florence Nightingale and statistics: what she did and what she did not. Radical Statistics. 2021;(128):14-34.
7. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;2(4582):769-82.
8. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.
9. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. Washington (DC): US Government Printing Office; 1979.
10. Brandt AM. Racism and research: the case of the Tuskegee Syphilis Study. Hastings Cent Rep. 1978;8(6):21-9.
11. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-91.
12. Kijewski S, McBride C, Owens E, Bernheim E, Vayena E. Decentralized clinical trials: A comprehensive analysis of trends, technologies, and global challenges. PLOS Digit Health. 2026 Jan 16;5(1):e0001191.
13. FDA. Real-world evidence. Silver Spring (MD): US Food and Drug Administration; 2024.
14. Oh SS, Galanter J, Thakur N, et al. Diversity in clinical and biomedical research: a promise yet to be fulfilled. PLoS Med. 2015;12(12):e1001918.
15. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard—lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175-81.
16. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53.
17. FDA. Artificial intelligence and machine learning in software as a medical device. Silver Spring (MD): US Food and Drug Administration; 2021.